Biomedicines (Jan 2024)

<i>IKZF1</i> Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia

  • Jonathan Paolino,
  • Harrison K. Tsai,
  • Marian H. Harris,
  • Yana Pikman

DOI
https://doi.org/10.3390/biomedicines12010089
Journal volume & issue
Vol. 12, no. 1
p. 89

Abstract

Read online

IKZF1 encodes the transcription factor IKAROS, a zinc finger DNA-binding protein with a key role in lymphoid lineage development. IKAROS plays a critical role in the development of lineage-restricted mature lymphocytes. Deletions within IKZF1 in B-cell acute lymphoblastic leukemia (B-ALL) lead to a loss of normal IKAROS function, conferring leukemic stem cell properties, including self-renewal and subsequent uncontrolled growth. IKZF1 deletions are associated with treatment resistance and inferior outcomes. Early identification of IKZF1 deletions in B-ALL may inform the intensification of therapy and other potential treatment strategies to improve outcomes in this high-risk leukemia.

Keywords